AG
SUPN icon

AmeriFlex Group’s Supernus Pharmaceuticals SUPN Stock Holding History

AmeriFlex Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$744 Buy
+16
New +$768 ﹤0.01% 1459

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

AmeriFlex Group's SUPN Position: Q2 2026 in Review

AmeriFlex Group opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 16 shares worth $744. The stake represents ﹤0.01% of the portfolio and ranks #1459 among its holdings.

332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • AmeriFlex Group held 16 shares of Supernus Pharmaceuticals worth $744 as of Q2 2026.
  • Supernus Pharmaceuticals was a new AmeriFlex Group position in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of AmeriFlex Group's portfolio in Q2 2026, its #1459 holding.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on AmeriFlex Group's 13F filing for Q2 2026, filed 14 Aug 2026.